What Is the Evidence for the Use of Botulinum Toxin in Idiopathic Detrusor Overactivity?

Abstract

There is growing evidence to support the use of botulinum toxin (BTX) in idiopathic detrusor overactivity. However, BTX remains off label for this purpose. In this commentary, we review the current status of the literature discussing the evidence for efficacy and safety of BTX. In addition, we present the data regarding the preparation, dose, and administration of BTX. As an emerging treatment, high-level evidence exists for the use of BTX in patients with idiopathic detrusor overactivity; however, details about the optimum number of injection sites and injection volume remain to be answered. In addition, longterm data regarding the effect of repeated injections requires further study.